Uncategorized
Genetic variation increases Covid-19 and lung disease risk

A genetic difference carried by nearly one in three could increase the risk of Covid-19 and lung disease, a new study shows.
Researchers at the University of Edinburgh found the genetic variant alters a newly discovered enzyme found in lung tissue, disrupting the function of a previously unknown protein. This hidden biological pathway could explain why some people are more susceptible to serious lung disease.
Experts warn the findings point to growing evidence that the human genome contains many previously overlooked proteins that may have important roles in health and disease. Understanding where these proteins are found in the body, how they change during disease and how genetic variation affects their function could determine the causes of disease, improve diagnosis and reveal new targets for treatment.
Researchers from the University of Edinburgh, with partners at the University of Sydney, investigated how genetic differences associated with both rare diseases and common conditions affect these newly identified proteins.
They found that many genetic variants previously thought not to affect proteins can alter the structure and function of these newly discovered molecules. These variants had remained hidden within poorly understood regions of the genome, limiting understanding of how they contribute to disease.
The findings suggest many disease-associated genetic variants act through proteins that have only recently been recognised, opening new opportunities to improve diagnosis and identify therapeutic targets.
“For decades, we have interpreted genetic variation through the lens of the proteins we knew existed,” said Dr Simon Biddie, of the University of Edinburgh’s Institute of Genetics and Cancer.
“Our findings show that many genetic changes linked to disease may actually act through previously hidden proteins that have only recently come to light. Understanding these proteins could transform how we diagnose genetic diseases and identify new targets for treatment.”
Discovery ‘opens up new avenues’ for therapies
The human genome contains around 20,000 genes, many of which can produce more than one protein. Some of these proteins are specific to particular tissues or diseases, but many have remained unknown until recently.
Genetic differences affecting these proteins have often been overlooked, limiting scientists’ understanding of how inherited genetic variation contributes to disease.
To better understand the role of these proteins, researchers developed a new method to measure their abundance within cells. The new method allows scientists to make measurements even at very low quantities in cells.
The team focused on a newly identified enzyme found in lung tissue, linked to infections, inflammation and lung cancer. They found that the variant changes the function of the enzyme and alters its response to a drug, providing new insight into how genetic differences may influence both disease risk and treatment response.
The team also identified similar genetic changes affecting newly discovered proteins that may influence vitamin D levels and contribute to kidney or heart disease. Some of these variants are common, affecting nearly 50% of the population, but are likely to have only modest effects on disease risk. Others are extremely rare – affecting as few as one in a million people – but are thought to cause more severe forms of disease.
Professor Mark Gorrell, from the Centenary Institute and the University of Sydney, first discovered the enzyme and was part of the team for this study.
“This new research both explains the association of the enzyme with lung diseases and opens up new avenues to understand this enzyme in disease and help us devise potential therapies,” Gorrell said.
The post Genetic variation increases Covid-19 and lung disease risk appeared first on Drug Discovery World (DDW).
Uncategorized
New webinar: Tackling drug discovery challenges in cancer research

Hosted by Drug Discovery World and supported by Sartorius and BioIVT, this webinar will explore the opportunities and challenges that exist within cancer research drug discovery and development.
You will hear from Dr Sudha Rao, Chief Scientific Officer of Kazia Therapeutics, Karol Budzik, PhD, Business Development Associate at Vyriad Therapeutics and Lars van der Veen, Chief Scientific Officer at iOnctura.
Presentations will cover how cancer treatments have shifted towards reprogramming the biology driving tumour growth, immune escape and treatment resistance, the trajectory that in vivo CAR-T treatments are taking, and how challenging tumours burdened by stroma and immune-mediated resistance can be tackled.
Q&A with the speakers follows the presentations.
The post New webinar: Tackling drug discovery challenges in cancer research appeared first on Drug Discovery World (DDW).
Uncategorized
Psilocybin proves promising in neuropathic pain mouse study
Amid the rise of psychedelics in the mental health space, researchers have begun to explore psilocybin as a treatment for chemotherapy-induced peripheral neuropathy.
Uncategorized
New Spectrometry Technique Could Aid Formulation Development
New Spectrometry Technique Could Aid Formulation Development
A new technique combining two forms of spectrometry could help biopharmaceutical companies improve their choice of formulation buffer for antibody manufacturing by revealing how molecular forms and three-dimensional shapes of complex biologics respond to their environment. That’s the view of Christian Bleiholder, PhD, a professor at Florida State University who helped develop the technique.
According to Bleiholder, what happens structurally when a complex biological molecule, such as an antibody or viral spike protein, binds to its target is currently poorly understood.
“This is where [this approach] can help with the bioprocessing and formulation,” he says, as structural changes “can affect the lifespan [of the product] and lead to issues, such as aggregation.”
Because antibodies are complex, existing techniques tend to be powerful at different levels of complexity, he explains. Mass spectrometry is particularly powerful for distinguishing molecular composition, while structural approaches such as X-ray crystallography and cryo-electron microscopy can provide high-resolution structural information.
The challenge is understanding the link between these things within a heterogeneous sample, he says.
To overcome this, Bleiholder and his team worked with Bruker Daltonics to develop Tandem-Trapped Ion Mobility Spectrometry (Tandem-TIMS). This combines tandem ion mobility spectrometry with tandem mass spectrometry to disentangle three overlapping layers of molecular complexity: molecular form, three-dimensional shape, and binding or assembly state, he says.
He explains that, if the proteins have different structures, they can be characterized with tandem ion mobility spectrometry, and then mass spectrometry can be used to look at their molecular forms and binding states.
Going forward, Bleiholder hopes the technique can be used for formulation development but also earlier, during drug discovery of new products, such as multi-specific antibodies, to determine which molecular states are important and how those change when a biologic engages its target. He also plans to look at automating the technique.
Bleiholder spoke about using Tandem-TIMS at the Bioprocessing Summit in Boston earlier this year.
The post New Spectrometry Technique Could Aid Formulation Development appeared first on GEN – Genetic Engineering and Biotechnology News.
-
Uncategorized8 months agoNovartis buys Synnovation’s PI3Kα inhibitors for $3 billion
-
Endpoints News8 months ago
Novartis to pay $2B upfront to take next-gen PI3Kα inhibitor from Synnovation
-
Uncategorized7 months agoOptical Pooled CRISPR Screen Reveals Regulators of NF-κB Dynamics in Human Cells
-
Uncategorized6 months ago
Relay’s PI3Kα inhibitor clears efficacy bar in Phase 2 vascular anomalies study
-
Uncategorized5 months ago
Hybrid solid−liquid optics enable scalable, high-resolution light-sheet microscopy across diverse immersion media
-
Fierce Biotech8 months ago
Scientists turn pig semen extract into eye drops that kill cancer in mice
-
Nature Biotechnology8 months ago
Sustained nitric oxide production by engineered E. coli remodels the tumor microenvironment and potentiates immunotherapy
-
BioPharma Dive – AI / Data8 months agoAstraZeneca lung drug gets ‘surprise’ win in COPD trials
Scan to Read